The US FDA has approved denosumab-desu, a RANK ligand inhibitor biosimilar to denosumab, used in the treatment of osteoporosis. Clinical evidence In a clinical study, denosumab-desu demonstrated comparable safety and efficacy to its reference drug.
Dosage and administration Available as a subcutaneous injection Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen Instruct patients to take calcium 1000 mg daily and at least 400 IU vitamin D daily Contraindications Hypocalcemia Warnings and precautions Same active ingredient Hypocalcemia Serious infections, including skin infections Dermatologic reactions Osteonecrosis of the jaw Suppression of bone turnover Adverse reactions Postmenopausal osteoporosis: Back pain, pain in extremity, hypercholesterolemia, musculoskeletal pain, cystitis and pancreatitis Bone loss due to hormone ablation…
